Conferences - Results from #140

AUA 2022: De-Intensifying Active Surveillance for Prostate Cancer May 15, 2022

AUA 2022: Is Cytoreductive Nephrectomy Dead or Alive in 2022? May 15, 2022

AUA 2022: Addressing Racial Disparities in Urologic Cancer May 15, 2022

AUA 2022: AUA Guidelines: Localized Prostate Cancer May 15, 2022

AUA 2022: Real-time Bladder Tumor Detection at Clinics in Flexible Cystoscopy with White Light and Narrow Band Imaging using Deep Learning May 15, 2022

AUA 2022: En-Bloc Versus Conventional Transurethral Resection of Bladder Tumors: Single-Center Prospective Randomized Trial May 15, 2022

AUA 2022: Should Everyone Receive Adjuvant Therapy after Resection of High-Risk RCC? May 15, 2022

AUA 2022: A Randomized Study to Compare Outcomes of Intravesical Chemohyperthermia with Mitomycin C Versus Intravesical BCG for Intermediate and High Risk NMIBC May 15, 2022

AUA 2022: Reliability of 68Ga-PSMA PET/CT in Assessing Real Nodal Burden in Men With cN1 Disease: Clinical Implications for Patient Counselling and Multi-Modal Treatments May 14, 2022

AUA 2022: Robot-Assisted PSMA-radioguided Salvage Surgery in Recurrent Prostate Cancer Using a DROP-IN Gamma Probe - a Prospective Feasibility Study May 14, 2022

AUA 2022: Tips and Tricks in IVC Thrombectomy May 14, 2022

AUA 2022: Management of Incidentally Discovered 3 cm Solid Renal Mass Cancer May 14, 2022

AUA 2022: Comparison Between Targeted versus Targeted Plus Standard Biopsy for Prostate Cancer Diagnosis in Biopsy Naïve Patients: A Randomized Controlled Trial May 14, 2022

AUA 2022: Not All Adverse Pathology Features Are Equal: Identifying Optimal Candidates For Adjuvant Radiotherapy Among Patients With Adverse Pathology at Radical Prostatectomy May 14, 2022

AUA 2022: The Impact Of Primary Tumor Size On Cancer-Specific And All-Cause Mortality In Patients Undergoing Cytoreductive Nephrectomy For Metastatic Renal Cell Carcinoma: Analysis From The International Marker Consortium For Renal Cancer May 14, 2022

AUA 2022: Overall Survival in Patients with Metastatic Hormone-Sensitive Prostate Cancer Treated with Enzalutamide or Placebo Plus Androgen Deprivation Therapy Who Had Prior Local Therapy: Post Hoc Analysis of the Phase 3 ARCHES Trial May 14, 2022

AUA 2022: Niraparib with Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer: Results from the Phase 2 QUEST Study May 14, 2022

AUA 2022: Comparison of Clinical Outcomes Between Androgen Deprivation Therapy with Up-Front Abiraterone and Bicalutamide for Japanese Patients with LATITUDE High-Risk Prostate Cancer in a Real-World Multicenter Analysis May 14, 2022

AUA 2022: Disparities Regarding Shared Decision-Making in Prostate Cancer Screening May 14, 2022

AUA 2022: Racial and Ethnic Disparities Magnified After U.S. Preventative Services Task Force Category D Recommendation for PSA Screening May 14, 2022

Page 8 of 465

email news signup